We are live on ! Find out more
GTBP icon

GT Biopharma

29 hedge funds and large institutions have $4.36M invested in GT Biopharma in 2022 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 10 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

2.21% less ownership

Funds ownership: 10.19% → 7.98% (-2.2%)

26% less funds holding

Funds holding: 39 → 29 (-10)

50% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 10

83% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 12

87% less capital inflows, than outflows

Capital inflows: $264K | Capital outflows: $2.04M

Holders
29
Holders Change
-10
Holders Change %
-25.64%
% of All Funds
0.5%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
5
Reduced
10
Closed
12
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

GTBP Hedge Fund Activity: Q3 2022 in Review

29 of the 5,834 institutional investors tracked by Wall St. Rank reported a position in GT Biopharma (GTBP) for Q3 2022, worth a combined $4.36M — down 53% from $9.28M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of GTBP and 2 opened new positions — a net loss of 10 holders — while 10 trimmed existing stakes and 5 added.

The largest buyer was Jane Street, opening a new position worth an estimated $84.1K. The largest seller was Morgan Stanley, cutting an estimated $333K.

  • 29 institutional investors held GT Biopharma (GTBP) as of Q3 2022, down from 39 in Q2 2022.
  • Funds reported $4.36M of GT Biopharma stock for Q3 2022, down 53% quarter-over-quarter.
  • 2 funds opened new GT Biopharma positions in Q3 2022 and 12 closed out, a net change of -10 holders.
  • The largest GT Biopharma buyer in Q3 2022 was Jane Street, an estimated $84.1K added.
  • The largest GT Biopharma seller in Q3 2022 was Morgan Stanley, an estimated $333K sold.

Based on aggregated 13F filings for Q3 2022.